Business Context and Reporting Period
This unaudited Form 10-Q is for Brooks Automation, Inc. (now associated with the requested Azenta, Inc. metadata) for the quarter and nine months ended June 30, 2015, within fiscal 2015. Brooks provides automation, cryogenic, semiconductor equipment and life-science solutions through Brooks Product Solutions, Brooks Global Services and Brooks Life Science Systems.
Comparisons are to the three and nine months ended June 30, 2014. The Granville-Phillips business was sold in May 2014 and is presented as a discontinued operation; continuing-operations comparisons exclude that business.
Key Financial Metrics
| Metric | Three months ended June 30, 2015 | Three months ended June 30, 2014 | Nine months ended June 30, 2015 | Nine months ended June 30, 2014 |
|---|---|---|---|---|
| Total revenue | $144.9 million | $117.4 million | $406.9 million | $360.3 million |
| Gross profit | $51.2 million | $40.7 million | $136.3 million | $125.9 million |
| Gross margin | 35.3% | 34.7% | 33.5% | 34.9% |
| Operating income (loss) | $10.2 million | $(5.9) million | $6.7 million | $(2.1) million |
| Income from continuing operations | $7.7 million | $(2.8) million | $7.7 million | $1.3 million |
| Net income attributable to Brooks | $7.7 million | $24.5 million | $7.7 million | $31.1 million |
| Diluted EPS | $0.11 | $0.36 | $0.11 | $0.46 |
| Operating cash flow | Not separately provided | Not separately provided | $21.5 million | $40.3 million |
Revenue increased 23% year over year in the quarter and 13% for the nine-month period. Quarterly operating margin was approximately 7.0%, compared with a negative margin in the prior-year quarter; nine-month operating margin was approximately 1.7%, compared with a negative margin in the prior-year period.
- Product revenue increased 30% for the quarter and 17% for the nine-month period.
- Services revenue was essentially flat for the quarter and declined 2% for the nine-month period.
- Brooks Product Solutions revenue increased 39% in the quarter and 16% for the nine-month period, driven by organic growth and DMS acquisition revenue.
- Brooks Life Science Systems revenue declined 8% in the quarter but increased 18% for the nine-month period, primarily due to FluidX revenue.
Balance Sheet, Liquidity and Capital Structure
- Cash and cash equivalents were $79.7 million at June 30, 2015, compared with $94.1 million at September 30, 2014.
- Short- and long-term marketable securities totaled $135.0 million, resulting in cash, cash equivalents and marketable securities of $214.6 million.
- Total liabilities were $139.1 million and total equity was $631.2 million.
- The company had $7.9 million of capital lease obligations, including $0.9 million due within twelve months. The filing does not report conventional funded bank debt.
- Accounts receivable increased to $101.0 million from $80.1 million, while inventory increased modestly to $95.2 million from $93.6 million.
- Cash flow from operations was $21.5 million. Investing cash flow was $(12.7) million and financing cash flow was $(19.7) million, principally reflecting $20.2 million of dividends.
- Capital expenditures were $5.9 million, and the company paid $15.5 million for FluidX, $5.0 million for BioCision convertible debt securities and warrants, and $1.8 million for YBA assets.
- Letters of credit outstanding totaled approximately $5.9 million, primarily supporting customer advances and performance obligations.
Material Changes Versus the Prior Comparable Period
- Continuing-operations profitability improved materially, with quarterly operating income of $10.2 million versus a $5.9 million operating loss and nine-month operating income of $6.7 million versus a $2.1 million loss.
- Net income declined despite improved continuing operations because the prior-year periods included $27.3 million and $30.0 million of after-tax income from the sold Granville-Phillips business.
- Quarterly gross margin improved by 60 basis points, but nine-month gross margin declined by 140 basis points. Life Science Systems margins fell sharply to 27.8% for the quarter and 26.2% for the nine-month period, versus 35.5% and 36.5%, respectively.
- FluidX contributed $3.8 million of quarterly revenue and $11.2 million of nine-month revenue, but recorded net losses of $0.3 million and $0.5 million, respectively.
- DMS contributed $11.0 million of quarterly revenue and $27.1 million of nine-month revenue.
- Restructuring charges declined to $0.4 million for the quarter from $3.1 million, and to $3.7 million for the nine-month period from $4.6 million.
- Foreign currency movements reduced revenue by $2.3 million for the quarter and $5.0 million for the nine-month period.
Guidance, Outlook, Risks and Unusual Items
Management stated that available resources were adequate for currently planned working capital and capital expenditures for the next twelve months, but cautioned that semiconductor capital-equipment demand is cyclical and longer-term liquidity needs are difficult to predict. No specific revenue or earnings guidance was provided in the filing.
- The company planned to close its Mistlegau, Germany manufacturing site in fiscal 2016 and continued transitioning selected manufacturing activities to third-party contract manufacturers.
- Life Science Systems results were pressured by cost overruns and schedule shortfalls in large-store systems, higher installation costs, lower manufacturing absorption and manufacturing-consolidation costs.
- The company completed the dissolution process for the Yaskawa Brooks Automation joint venture; remaining liquidation and distribution activities were expected by fiscal year-end.
- The company recorded a $0.7 million impairment related to its YBA equity investment during the nine-month period.
- A strategic-partner note receivable had a $1.3 million carrying value at June 30, 2015 after a prior-year $2.6 million impairment. No new impairment trigger was identified during the current quarter.
- The company had one customer representing 11% of quarterly revenue and 12% of nine-month revenue, creating customer-concentration exposure.
- Legal proceedings were described as arising in the ordinary course; management did not believe they would have a material adverse effect, while acknowledging that outcomes remain uncertain.
- Tax audits and unrecognized tax benefits remain potential sources of volatility. Approximately $1.3 million of unrecognized tax benefits could be reduced within twelve months due to statute-of-limitations expirations.
- Market risk disclosures indicated that a hypothetical 100-basis-point interest-rate change would affect annual interest income by approximately $2.2 million, while a hypothetical 10% foreign-exchange change would affect net income by approximately $0.8 million.
- The board declared a subsequent $0.10-per-share dividend payable September 25, 2015. Future dividends remain discretionary and could be reduced, delayed or canceled during a severe cyclical downturn.
Important Facts for Investors to Verify
- Confirm the corporate-name relationship between the requested Azenta, Inc. metadata and the filing’s registrant, Brooks Automation, Inc.
- Assess the sustainability of improved Product Solutions profitability against semiconductor-cycle volatility and the decline in Life Science Systems margins.
- Review working-capital conversion, particularly the $19.1 million increase in accounts receivable and the reduction in operating cash flow versus the prior year.
- Evaluate the financial performance and integration costs of FluidX and DMS, including purchase-accounting inventory step-ups and acquired-intangible amortization.
- Monitor restructuring execution, the planned Mistlegau site closure and manufacturing outsourcing costs.
- Review customer concentration, foreign-exchange exposure, letters of credit, capital-lease obligations and the recoverability of the strategic-partner note receivable.
- Separate continuing operating performance from the prior-year Granville-Phillips discontinued-operation gain when evaluating earnings trends.